Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma

We determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of imatinib mesylate, an inhibitor of the receptor tyrosine kinases platelet-derived growth factor receptor (PDGFR), the proto-oncogene product c-kit, and the fusion protein Bcr-Abl, when administered for 8 days in combi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Reardon, David A., Desjardins, Annick, Vredenburgh, James J., Sathornsumetee, Sith, Rich, Jeremy N., Quinn, Jennifer A., Lagattuta, Theodore F., Egorin, Merrill J., Gururangan, Sridharan, McLendon, Roger, Herndon, James E., Friedman, Allan H., Salvado, August J., Friedman, Henry S.
Format: Artigo
Idioma:Inglês
Publicat: Duke University Press 2008
Matèries:
Clinical Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2563055/
https://ncbi.nlm.nih.gov/pubmed/18359865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2008-003
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars